Professor Dale Godfrey was awarded his PhD in 1990 from Monash University and then worked as a postdoc Hoffman-La Roche in New Jersey, USA and then DNAX Research Institute in Palo Alto, USA. He returned to the Centenary Institute at The University of Sydney in 1994, then returned to Monash University, Department of Immunology, as a Research Fellow and Senior Research Fellow. In 2003, Dale moved to The University of Melbourne, Department of Microbiology and Immunology, where he now works as an NHMRC L3 Investigator Fellow.
Godfrey is also a Fellow of the Australian Academy for Health and Medical Sciences, Past President of the Australasian Society for Immunology, and founder and Past President of the Melbourne Immunotherapy Network. Godfrey’s area of interest has for many years been in the field of unconventional T cells including their development, function and therapeutic potential. With the arrival of COVID in 2020, Godfrey switched some of his lab’s expertise toward research into ways to combat what was clearly a serious problem. This work resulted in a prototype point of care SARS-CoV-2 neutralising antibody test, SARS-CoV-2 neutralising nanobodies, as well as a protein subunit SARS-CoV-2 vaccine which has just completed a phase I clinical trial.